Shandong Weigao Group Medical Polymer Company Limited (abbreviated as WEIGAO GROUP) disclosed a next-day return confirming an on-market repurchase of 120,000 H-shares on 24 April 2026. The shares were bought at prices ranging between HKD 3.60 and HKD 3.71, equivalent to a volume-weighted average of HKD 3.6733 per share and an aggregate consideration of HKD 0.44 million.

Following the transaction: • Issued shares (excluding treasury shares) declined marginally by 0.0027% to 4.47 billion. • Treasury shares increased from 52.63 million to 52.75 million, while total issued shares remained at 4.52 billion. • The repurchased shares will be held as treasury shares; none have been cancelled to date.

Repurchase mandate status: • The current mandate, approved on 27 May 2025, authorises the buyback of up to 451.56 million shares. • To date, 46.10 million shares have been repurchased under this mandate, representing 10.21% of the share base at the approval date. • A moratorium on new share issues or treasury-share sales remains in effect until 25 May 2026, in accordance with listing rules.

The company confirmed that all repurchase procedures complied with Hong Kong Stock Exchange regulations and relevant legal requirements.